Annual Accounts Receivable
$15.39 M
+$15.39 M+100.00%
December 31, 2022
Summary
- As of February 10, 2025, CTIC annual accounts receivable is $15.39 million, with the most recent change of +$15.39 million (+100.00%) on December 31, 2022.
Performance
CTIC Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly Accounts Receivable
$22.96 M
+$7.57 M+49.20%
March 31, 2023
Summary
- As of February 10, 2025, CTIC quarterly accounts receivable is $22.96 million, with the most recent change of +$7.57 million (+49.20%) on March 31, 2023.
- Over the past year, CTIC quarterly accounts receivable has increased by +$20.53 million (+846.29%).
Performance
CTIC Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
CTIC Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +100.0% | +846.3% |
| 3 y3 years | - | - |
| 5 y5 years | +1104.0% | +100.0% |
CTIC Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | -100.0% | at high | -100.0% |
| 5 y | 5-year | at high | -100.0% | at high | -100.0% |
| alltime | all time | at high | -100.0% | at high | -100.0% |
CTI BioPharma Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2023 | - | $22.96 M(+49.2%) |
| Dec 2022 | $15.39 M(>+9900.0%) | $15.39 M(+45.3%) |
| Sep 2022 | - | $10.59 M(+29.8%) |
| Jun 2022 | - | $8.16 M(+236.3%) |
| Mar 2022 | - | $2.43 M(>+9900.0%) |
| Dec 2021 | $0.00(-100.0%) | $0.00(-100.0%) |
| Sep 2019 | - | $137.00 K(-61.5%) |
| Jun 2019 | - | $356.00 K(-56.6%) |
| Mar 2019 | - | $821.00 K(-94.0%) |
| Dec 2018 | $13.68 M(+970.3%) | $13.68 M(>+9900.0%) |
| Mar 2018 | - | $0.00(-100.0%) |
| Dec 2017 | $1.28 M(+238.1%) | $1.28 M(+610.0%) |
| Sep 2017 | - | $180.00 K(-62.5%) |
| Jun 2017 | - | $480.00 K(+54.3%) |
| Mar 2017 | - | $311.00 K(-17.7%) |
| Dec 2016 | $378.00 K(+34.0%) | $378.00 K(-39.0%) |
| Sep 2016 | - | $620.00 K(+10.9%) |
| Jun 2016 | - | $559.00 K(-16.1%) |
| Mar 2016 | - | $666.00 K(+136.2%) |
| Dec 2015 | $282.00 K(-86.0%) | $282.00 K(-33.2%) |
| Sep 2015 | - | $422.00 K(-52.0%) |
| Jun 2015 | - | $880.00 K(-30.8%) |
| Mar 2015 | - | $1.27 M(-36.7%) |
| Dec 2014 | $2.01 M(+755.7%) | $2.01 M(+70.9%) |
| Sep 2014 | - | $1.18 M(+92.0%) |
| Jun 2014 | - | $613.00 K(+21.9%) |
| Mar 2014 | - | $503.00 K(+114.0%) |
| Dec 2013 | $235.00 K(>+9900.0%) | $235.00 K(-56.5%) |
| Sep 2013 | - | $540.00 K(-30.9%) |
| Jun 2013 | - | $782.00 K(+1.8%) |
| Mar 2013 | - | $768.00 K(>+9900.0%) |
| Dec 2012 | $0.00 | $0.00(0.0%) |
| Sep 2009 | - | $0.00(0.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2009 | - | $0.00(0.0%) |
| Mar 2009 | - | $0.00(-100.0%) |
| Dec 2008 | $982.00 K(+1825.5%) | $982.00 K(-38.2%) |
| Sep 2008 | - | $1.59 M(-10.7%) |
| Jun 2008 | - | $1.78 M(-7.6%) |
| Mar 2008 | - | $1.93 M(+3676.5%) |
| Dec 2007 | $51.00 K(-72.1%) | $51.00 K(-68.5%) |
| Jun 2007 | - | $162.00 K(-16.5%) |
| Mar 2007 | - | $194.00 K(+6.0%) |
| Dec 2006 | $183.00 K(-92.1%) | $183.00 K(-46.0%) |
| Sep 2006 | - | $339.00 K(-33.5%) |
| Jun 2006 | - | $510.00 K(+22.0%) |
| Mar 2006 | - | $418.00 K(-81.9%) |
| Dec 2005 | $2.31 M(+162.3%) | $2.31 M(-13.9%) |
| Sep 2005 | - | $2.68 M(+5481.3%) |
| Jun 2005 | - | $48.00 K(-97.2%) |
| Mar 2005 | - | $1.72 M(+95.4%) |
| Dec 2004 | $879.00 K(-55.6%) | $879.00 K(-45.1%) |
| Sep 2004 | - | $1.60 M(+44.2%) |
| Jun 2004 | - | $1.11 M(+5.5%) |
| Mar 2004 | - | $1.05 M(-46.8%) |
| Dec 2003 | $1.98 M(-7.9%) | $1.98 M(+155.5%) |
| Sep 2003 | - | $775.00 K(-50.4%) |
| Jun 2003 | - | $1.56 M(+44.4%) |
| Mar 2003 | - | $1.08 M(-49.7%) |
| Dec 2002 | $2.15 M(+48.0%) | $2.15 M(+91.8%) |
| Sep 2002 | - | $1.12 M(-11.5%) |
| Jun 2002 | - | $1.27 M(+69.5%) |
| Mar 2002 | - | $747.00 K(-48.6%) |
| Dec 2001 | $1.45 M(-11.2%) | $1.45 M(+101.5%) |
| Sep 2001 | - | $721.00 K(-18.6%) |
| Jun 2001 | - | $885.30 K(+145.6%) |
| Mar 2001 | - | $360.50 K(-78.0%) |
| Dec 2000 | $1.64 M | $1.64 M |
FAQ
- What is CTI BioPharma annual accounts receivable?
- What is the all time high annual accounts receivable for CTI BioPharma?
- What is CTI BioPharma annual accounts receivable year-on-year change?
- What is CTI BioPharma quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for CTI BioPharma?
- What is CTI BioPharma quarterly accounts receivable year-on-year change?
What is CTI BioPharma annual accounts receivable?
The current annual accounts receivable of CTIC is $15.39 M
What is the all time high annual accounts receivable for CTI BioPharma?
CTI BioPharma all-time high annual accounts receivable is $15.39 M
What is CTI BioPharma annual accounts receivable year-on-year change?
Over the past year, CTIC annual accounts receivable has changed by +$15.39 M (+100.00%)
What is CTI BioPharma quarterly accounts receivable?
The current quarterly accounts receivable of CTIC is $22.96 M
What is the all time high quarterly accounts receivable for CTI BioPharma?
CTI BioPharma all-time high quarterly accounts receivable is $22.96 M
What is CTI BioPharma quarterly accounts receivable year-on-year change?
Over the past year, CTIC quarterly accounts receivable has changed by +$20.53 M (+846.29%)